Zurcher Kantonalbank Zurich Cantonalbank decreased its position in shares of Core Laboratories (NYSE:CLB) by 78.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,399 shares of the oil and gas company’s stock after selling 8,578 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Core Laboratories were worth $263,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. WCM Investment Management CA raised its position in Core Laboratories by 2.5% in the 3rd quarter. WCM Investment Management CA now owns 4,542,901 shares of the oil and gas company’s stock valued at $448,385,000 after purchasing an additional 109,726 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its position in Core Laboratories by 19.0% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 2,025,357 shares of the oil and gas company’s stock valued at $199,904,000 after purchasing an additional 323,357 shares in the last quarter. Earnest Partners LLC raised its position in Core Laboratories by 6.3% in the 3rd quarter. Earnest Partners LLC now owns 1,951,719 shares of the oil and gas company’s stock valued at $192,635,000 after purchasing an additional 115,982 shares in the last quarter. JPMorgan Chase & Co. raised its position in Core Laboratories by 14.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 935,695 shares of the oil and gas company’s stock valued at $91,904,000 after purchasing an additional 121,553 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its position in shares of Core Laboratories by 10.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 895,405 shares of the oil and gas company’s stock worth $88,373,000 after acquiring an additional 86,407 shares in the last quarter.
Several brokerages have recently weighed in on CLB. TheStreet raised Core Laboratories from a “c” rating to a “b-” rating in a research report on Thursday, February 1st. Piper Jaffray Companies began coverage on Core Laboratories in a research report on Tuesday. They set a “neutral” rating and a $96.00 target price on the stock. ABN Amro lowered Core Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Royal Bank of Canada set a $125.00 target price on Core Laboratories and gave the stock a “buy” rating in a research report on Tuesday, January 30th. Finally, Deutsche Bank lowered Core Laboratories from a “buy” rating to a “hold” rating and cut their target price for the stock from $116.30 to $109.00 in a research report on Thursday, January 11th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the company’s stock. Core Laboratories has an average rating of “Hold” and an average price target of $111.60.
Core Laboratories (NYSE:CLB) traded up $1.15 during trading hours on Wednesday, reaching $107.94. The company had a trading volume of 333,090 shares, compared to its average volume of 531,861. The stock has a market cap of $4,770.00, a P/E ratio of 56.51 and a beta of 1.47. The company has a quick ratio of 1.66, a current ratio of 1.98 and a debt-to-equity ratio of 1.53. Core Laboratories has a 12-month low of $86.55 and a 12-month high of $121.39.
Core Laboratories (NYSE:CLB) last released its quarterly earnings results on Wednesday, January 31st. The oil and gas company reported $0.58 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.58. The firm had revenue of $172.00 million for the quarter, compared to the consensus estimate of $171.92 million. Core Laboratories had a return on equity of 58.25% and a net margin of 12.60%. The firm’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.41 EPS. equities research analysts predict that Core Laboratories will post 2.66 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, February 16th. Investors of record on Friday, January 26th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Thursday, January 25th. This represents a $2.20 dividend on an annualized basis and a yield of 2.04%. Core Laboratories’s dividend payout ratio is presently 115.18%.
TRADEMARK VIOLATION NOTICE: “Zurcher Kantonalbank Zurich Cantonalbank Has $263,000 Holdings in Core Laboratories (CLB)” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2018/03/15/core-laboratories-clb-holdings-reduced-by-zurcher-kantonalbank-zurich-cantonalbank.html.
About Core Laboratories
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.